

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/088546 A1

(51) International Patent Classification:
C07K 16/00 (2006.01)

(21) International Application Number:
PCT/IB2024/060489

(22) International Filing Date:
24 October 2024 (24.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/593,011 25 October 2023 (25.10.2023) US
63/638,212 24 April 2024 (24.04.2024) US

(71) Applicant: ABLYNX N.V. [BE/BE]; Technologiepark 21,
9052 Zwijnaarde (BE).

(72) Inventors: JAWORSKI, Julie A.; c/o Sanofi, Patent De-
partment, 450 Water Street, Cambridge, Massachusetts
02141 (US). KATHURIA, Sagar V.; c/o Sanofi, Patent
Department, 450 Water Street, Cambridge, Massachusetts
02141 (US). MACKNESS, Brian; c/o Sanofi, Patent De-
partment, 450 Water Street, Cambridge, Massachusetts
02141 (US). PARK, Sunghae; c/o Sanofi, Patent Depart-
ment, 450 Water Street, Cambridge, Massachusetts 02141
(US). SUN, Victor Zhao; c/o Sanofi, Patent Department,
450 Water Street, Cambridge, Massachusetts 02141 (US).
ZHOU, Qun; c/o Sanofi, Patent Department, 450 Water
Street, Cambridge, Massachusetts 02141 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: FC DOMAIN VARIANTS WITH ENHANCED FC RECEPTOR BINDING

(57) Abstract: The present disclosure provides Fc domain variant polypeptides, including effector-competent Fc domain variants. The present disclosure also provides Fc domain variant polypeptides comprising at least one substitution or at least two substitutions at amino acid positions 251, 267, 268, 298, 314, 330, 339, 373, and 376, according to EU numbering, as compared to a Fc domain parent polypeptide. The present disclosure also provides nucleic acids encoding Fc domain variant polypeptides and host cells for making Fc domain variant polypeptides. Methods for increasing the yield of Fc domain variant polypeptides, and methods of using Fc domain variant polypeptides to treat disease, are also provided.



WO 2025/088546 A1